This study aims to evaluate whether a biomarker-guided treatment optimization strategy for heart failure patients leads to better clinical outcomes compared to usual care. The STROMG-HF trial will randomize 2000 patients with chronic heart failure to either biomarker-guided treatment optimization every 3 months based on NT-proBNP and GDF-15 levels or usual care. The primary outcome is a composite of cardiovascular death or heart failure hospitalization.